




# What's hot in diabetes nursing?

## June 2026






Too busy to keep up to date with the latest developments relating to diabetes nursing? In this regular feature, we carefully select the best resources, publications and research for all nurses with an interest in diabetes. Follow the links to access the full materials.

Citation: Milne N, Brake J (2026) What's hot in diabetes nursing? June 2026. *Journal of Diabetes Nursing* 30: JDN426




### Medicines and devices

<b>Discontinuation of Levemir (insulin detemir): Joint guidance from ABCD and PCDO Society (Updated 27 May 2026)</b>	Updated guidance reflecting the current insulin supply status. Support for clinicians in appropriately selecting and safely prescribing alternative insulin therapy. Includes video discussion on implementation. (Source: ABCD and PCDO Society)	 
<b>Medicine Supply Notification</b>	Limited supply of Trurapi® (insulin aspart) 100 units/mL solution for injection 3 mL pre-filled Solostar pens. (Source: Dept of Health and Social Care)	


### Learning and events

<b>3<sup>rd</sup> London Conference of the PCDO Society</b>	Managing multiple long-term conditions in 2026: The power of integrated healthcare. Free 1-day conference (London, 1 July). (Source: Primary Care Diabetes & Obesity Society)	
<b>22<sup>nd</sup> National Conference of the Primary Care Diabetes &amp; Obesity Society</b>	Unravelling the complexities of care: Diabetes, obesity and associated conditions. 2-day conference (Birmingham, 18–19 November). (Source: Primary Care Diabetes & Obesity Society)	
<b>Introduction to Diabetes: Foundations for Nursing Practice webinar</b>	To raise understanding of diabetes, including diagnosis, risk factors and management, complications and nursing care. Online (Tues. 6 October, 3 hours). (Source: Royal College of Nursing)	
<b>JBDS-IP Inpatient Diabetes Conference 2026</b>	Latest research and best practice, and how to address challenges of managing diabetes in inpatient environments. (Leicester, Fri. 3 July) (Source: Association of British Clinical Diabetologists)	
<b>Monogenic Diabetes Training Course: Right Diagnosis, Right Treatment</b>	Two-day course to help clinicians (including experienced DSNs) recognise and treat people with MODY and other forms of monogenic diabetes. (Online 19–20 October) (Source: Diabetes Genes)	



## Resources

<b>Resources for women with PMOS</b>	Resources for women and HCPs explaining why PCOS is now known as polyendocrine metabolic ovarian syndrome. (Source: Monash Centre for Health Research and Implementation [Australia] and Verity)	 
<b>Breaking barriers in diabetes technology</b>	Recommendations on removing barriers to accessing or effectively using diabetes technology for some children and young people with type 1 diabetes. Includes resources for HCPs and families. (Source: Diabetes UK)	





## Report

<b>Insulin: supporting safe self-administration for patients in the community with a disability</b>	Investigation focusing on adults with diabetes who have not been supported to self-manage insulin as intended alongside a disability or impairment. (Source: Health Services Safety Investigations Body)	
---	---	---




## Guidance

<b>Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity</b>	Evidence-based recommendations contained in new NICE technology appraisal. (Source: NICE)	
<b>Diabetes in pregnancy: management from preconception to the postnatal period [Draft]</b>	NICE invites comments on the new and updated information in their consultation document. (Source: NICE)	







## Quick reads

<b>Discontinuation of Levemir (insulin detemir) – abbreviated ABCD/PCDOS guidance</b>	A brief summary of guidance to support safe switching to alternative insulin therapy in response to the discontinuation of Levemir. <b>[Open access]</b> (Source: <i>Diabetes &amp; Primary Care</i> )	
<b>How to assess fitness to drive</b>	Summary of the DVLA's updated <i>Assessing Fitness to Drive – a guide for medical professionals</i> . <b>[Open access]</b> (Source: <i>Diabetes &amp; Primary Care</i> )	
<b>12 of 12 trial participants are no longer injecting insulin, thanks to new immunosuppressive drug tegobrutart</b>	Targeted immunosuppressive drug shows strong potential in islet transplant recipients with long-standing type 1 diabetes. (Source: <i>Breakthrough T1D</i> )	
<b>MMMM – Maintaining Muscle on Mimetic Medications</b>	Practical advice to help people minimise muscle loss when prescribed GLP-1-based therapies. <b>[Open access]</b> (Source: <i>Diabetes &amp; Primary Care</i> )	

## Quick reads (cont'd)

<b>How to undertake a multiple long-term conditions review</b>	Delivery of holistic care to adults living with type 2 diabetes and one or more additional long-term condition. Updated in line with NG28. <b>[Open access]</b> (Source: <i>Diabetes &amp; Primary Care</i> )	
<b>Diabetes Distilled: Incretin therapies and endoscopy safety</b>	Risk of clinically significant residual gastric volume, precluding an adequate examination, in those who continue these drugs prior to the procedure. <b>[Open access]</b> (Source: <i>Diabetes &amp; Primary Care</i> )	
<b>Healthy life expectancy trends in the UK: a watershed moment</b>	Analysis of changes in healthy life expectancy in the UK over the past decade, of variations across local areas and how trends compare with other high-income countries. <b>[Open access]</b> (Source: <i>The Health Foundation</i> )	

## Journals: Articles

<b>Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process</b>	New, more accurate name reflecting condition's multisystem pathophysiology expected to enhance awareness, diagnosis and patient experience. <b>[Open access]</b> (Source: <i>The Lancet</i> )	
<b>Comparison of menopausal symptoms in women with and without type 2 diabetes mellitus: a cross-sectional study</b>	Women with type 2 diabetes may have a higher burden of genitourinary and sleep-related menopausal symptoms. <b>[Open access]</b> (Source: <i>Climacteric</i> )	
<b>Comparative effectiveness of combination therapy with SGLT-2 inhibitors and GLP-1 RAs compared with SGLT-2 inhibitors in individuals with type 2 diabetes: A prevalent new-user cohort study</b>	Findings suggest that sustained concurrent use of both drug classes may offer meaningful clinical benefits in routine practice. <b>[Open access]</b> (Source: <i>Diabetes, Obesity and Metabolism</i> )	
<b>Impact of depression on treatment progression in type 2 diabetes: A UK retrospective cohort study using the Clinical Practice Research Datalink Aurum database</b>	Depression associated with earlier treatment intensification and insulin initiation in type 2 diabetes, highlighting the importance of integrating mental health support into diabetes care. <b>[Open access]</b> (Source: <i>Primary Care Diabetes</i> )	
<b>Associations of combined genetic and lifestyle risks with incident type 2 diabetes in the UK Biobank</b>	Individuals at all levels of genetic risk can greatly mitigate their risk by adhering to a healthy lifestyle. <b>[Open access]</b> (Source: <i>Diabetes</i> )	
<b>Cost-effectiveness of the diabetes remission clinical trial (DiRECT)/Counterweight-Plus weight management programme, based on 5-year follow-up</b>	Costs of achieving remissions from type 2 diabetes with the programme offset within 5 years through reduced healthcare resource use. <b>[Open access]</b> (Source: <i>Diabetic Medicine</i> )	

## Journals: Articles (cont'd)

<p><b>Interrelationship between baseline HbA1c, SGLT-2 inhibitor use and risk of DKA in adults with type 2 diabetes: a systematic review and meta-analysis</b></p>	<p>Individuals with higher baseline HbA1c levels may be at increased risk of DKA when treated with SGLT2 inhibitors. <b>[Open access]</b> (Source: <i>Diabetes, Obesity and Metabolism</i>)</p>	
<p><b>Sarcopenia in Diabetes: A proposal on integrating muscle assessment and nutritional intervention in people living with diabetes</b></p>	<p>Consensus document on methodologies for screening and diagnosing sarcopenia in people with diabetes, including a stepwise algorithm. <b>[Open access]</b> (Source: <i>Diabetes Research and Clinical Practice</i>)</p>	
<p><b>Highly uncontrolled cardiovascular risk in emerging adults with paediatric-onset type 1 diabetes – a cross-sectional analysis from the Diabetes Prospective Follow-Up registry DPV</b></p>	<p>This population displays a high burden of pronounced and clinically actionable, modifiable CVD risk factors and significant treatment gaps. <b>[Open access]</b> (Source: <i>Diabetes, Obesity and Metabolism</i>)</p>	
<p><b>Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial</b></p>	<p>CGM supports significant improvements in glycaemic control compared with SMBG in people with type 2 diabetes on basal insulin therapy. <b>[Open access]</b> (Source: <i>The Lancet Diabetes &amp; Endocrinology</i>)</p>	
<p><b>Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1)</b></p>	<p>Phase 3 trial supports retatrutide's potential as an effective treatment for type 2 diabetes. <b>[Open access]</b> (Source: <i>The Lancet</i>)</p>	
<p><b>Diabetes and Femoral Fracture Patterns: A Nationwide Registry Study (1997–2021)</b></p>	<p>Increased incidence of femoral fractures and slightly higher odds of ST/FS than hip fractures in type 1 diabetes. (Source: <i>Diabetes Care</i>)</p>	
<p><b>Hepatic events prevention by antihyperglycemic therapies and intervention comparisons in type 2 diabetes: The HEPATIC-T2DM Network meta-analysis</b></p>	<p>Liver-specific risk reduction is not uniform across anti-hyperglycaemic drug classes. (Source: <i>Diabetes Care</i>)</p>	